Company: ICUI
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0000883984-25-000010
Chunk: 48

Company: ICU MEDICAL INC/DE
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 48
---
 the valuation assumptions used to determine the change in the fair market value of the respective PEO and non-PEO NEO equity awards for each respective year reflect the probable outcome of the performance vesting conditions as of each measurement date. See the tables below for additional information with respect to the equity award adjustments.

(4) Assumes $100 invested on December 31, 2019 in ICU Medical Inc.'s common stock and the NASDAQ Medical Supplies Index and that all dividends, if any, were reinvested. As permitted by SEC Rules, the peer group referenced for purpose of the TSR Comparison is the industry peer group used for purposes in Item 201(e) of Regulation S-K. The separate peer group used by the Compensation Committee for purposes of determining compensation paid to our executive officers is described on page 16.

(5) As noted in the CD&A, for 2024, the Compensation Committee determined that Adjusted EBITDAserves as one of the most important financial measurements of the Company's performance and shareholder value creation and, accordingly, was utilized as a component in the 2024 MIP and the LTI Program. Adjusted EBITDA is a non-GAAP measure. Our reconciliation of net income to Adjusted EBITDA is included in Annex A to this proxy statement.

Compensation Actually Paid to PEO

|   |     |                                                                                                                                                                            |     |    |     | 2024 |            |
|:--|:----|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:---|:----|:-----|-----------:|
|   |     | Summary Compensation Table - Total Compensation                                                                                                                            |     | -a |     | $    |  6,454,754 |
| - |     | Grant Date Fair Value of Stock Awards and Option Awards Granted in Fiscal Year as Reported in the Summary Compensation Table for 2024.                                     |     | -b |     | $    | -4,500,004 |
| + |     | Fair Value at 2024 Fiscal Year End of Outstanding and Unvested Stock Awards and Option Awards Granted in 2024                                                              |     | -c |     | $    | 16,033,654 |
| + |     | Change in Fair Value of Outstanding and Unvested Stock Awards and Option Awards Granted in Prior Fiscal Years That Remain Outstanding At 2024 Fiscal Year End              |     | -d |     | $    |  1,590,719 |
| + |     | Fair Value